FlowCam for Biopharma - AAV Aggregation Detection in Gene Therapies - Medical / Health Care - Pharmaceuticals
Assess the stability and quality of the next generation of biotherapeutics designed to treat cancer, immunize against pathogens, and address genetic disorders. Flow imaging microscopy detects aggregation of viral vectors such as AAVs, lentiviruses, and retroviruses as well as non-viral therapies like LNPs and exosomes.
Most popular related searches
gene therapy
viral vector
drug production
gene therapy drug
drug formulation
genetic disorder
gene therapy product
gene therapy production
biotherapeutics
injectable therapy
Use FlowCam to:
- Monitor viral and nonviral vector aggregation in gene therapy formulations and drug products during formulation and process design
- Distinguish between inherent vector aggregates, intrinsic particles like glass flakes, and extrinsic contaminants
- Obtain reliable particle size and concentration measurements recommended by USP <1788> to support quality control processes
- Characterize particles as small as 300 nm with industry-leading image quality
Formulation Development of Viral and Non-Viral Vectors
Like other parenteral biotherapeutics, injectables in gene therapy are subject to regulations like USP <788> that require particle testing to mitigate safety risks.
Flow imaging microscopy techniques allow for the identification and characterization of particle types in your formulation, enabling you to make formulation and process improvements during product development.
- Meet USP requirements and recommendations with FlowCam LO—a combined flow imaging and light obscuration instrument
- Detect gene vector aggregates such as LNP oligomers as small as 300 nm with FlowCam Nano
Stay in the loop!
Select your areas of interest to receive industry updates.